Publications by authors named "E Waubant"
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Evidence suggests that the gut microbiome may play a role in multiple sclerosis (MS). However, the majority of the studies have focused on gut bacterial communities; none have examined the fungal microbiota (mycobiota) in persons with pediatric-onset multiple sclerosis (POMS). We examined the gut mycobiota in persons with and without POMS through a cross-sectional examination of the gut mycobiota from 46 participants' stool samples (three groups: 18 POMS, 13 acquired monophasic demyelinating syndromes [monoADS], and 15 unaffected controls).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how seasonal temperature changes affect fatigue levels in multiple sclerosis (MS) patients, a common symptom of the disease.
- Fatigue was assessed using two different measurement tools: the Modified Fatigue Impact Scale (MFIS) and the Neuro-QoL fatigue score, with the results showing that MFIS scores were influenced by season and location, while Neuro-QoL scores were not.
- The findings suggest that the effect of temperature on MS-related fatigue varies based on the specific measurement tool used.
In multiple sclerosis (MS) the circulating metabolome is dysregulated, with indole lactate (ILA) being one of the most significantly reduced metabolites. We demonstrate that oral supplementation of ILA impacts key MS disease processes in two preclinical models. ILA reduces neuroinflammation by dampening immune cell activation as well as infiltration; and promotes remyelination and in vitro oligodendrocyte differentiation through the aryl hydrocarbon receptor (AhR).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how social determinants of health (SDOH) impact pediatric-onset multiple sclerosis (POMS), particularly in terms of adverse SDOH frequency and their effects on treatment and outcomes.
- Researchers conducted a retrospective analysis of data from the United States Network of Pediatric MS Centers, focusing on various demographic and clinical outcomes related to SDOH hardships.
- Findings indicated that 66% of participants faced social hardships, which influenced factors such as age at symptom onset, steroid treatment likelihood, study attrition risk, and overall health scores.